SCHEMBL6614920

SCHEMBL6614920

O=S(=O)(Nc1cscc1-c1ccccc1Cl)c1cc(Cl)c(Cl)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES2 Q9H7Z7 2/20 0.56
ACLY P53396 1/20 0.50
CCR2 P41597 3/20 0.43
CCR4 P51679 2/20 0.43
CCR1 P32246 1/20 0.43
PFKFB3 Q16875 1/20 0.42
KDM1A O60341 1/20 0.40
KIT P10721 1/20 0.38
BRAF P15056 1/20 0.38
PGAM1 P18669 1/20 0.37
PFKFB4 Q16877 1/20 0.36
PKM P14618 2/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
POLB P06746 1/20 0.36
CASP6 P55212 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PRNP P04156 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6613209 0.82 PTGES2 (0.48) PTGES2ACLYCCR2CCR4CCR1
SCHEMBL6694171 0.79 SLC40A1 (0.48) ACLYCCR2KDM1APGAM1GAA
SCHEMBL6611808 0.79 PTGES2 (0.55) PTGES2ACLYCCR2CCR4CCR1
SCHEMBL2762650 0.78 KDM1A (0.66) PTGES2KDM1APOLB
SCHEMBL5831168 0.77 PTGES2 (0.50) PTGES2ACLYCCR4KDM1APKM
SCHEMBL6612903 0.77 CCKBR (0.43) PTGES2ACLYCCR4KDM1APGAM1
SCHEMBL6609567 0.75 PTGES2 (0.46) PTGES2ACLYCCR4PFKFB3PKM
SCHEMBL6612943 0.75 MEN1 (0.53) PTGES2ACLYKDM1APGAM1GAA
SCHEMBL5830884 0.75 PTGES2 (0.48) PTGES2ACLYCCR2CCR4CCR1
SCHEMBL6616015 0.74 SLC40A1 (0.53) PTGES2CCR4PKMPOLBCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 PTGES2 1300/4885ACLY 707/4885CCR2 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.